Routine Lipid Management

DRUG2 trials

Sponsors

Amgen

Conditions

AtheromaAtherosclerotic PlaqueCardiovascular DiseaseCoronary Artery DiseaseCoronary RevascularizationHypercholesterolemiaMyocardial InfarctionStroke

Phase 4

EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction

Active, not recruitingNCT05284747

AmgenCardiovascular Disease, Myocardial Infarction, Stroke +1

Start: 2022-10-26End: 2027-05-29Updated: 2025-10-06

A Trial Assessing the Effectiveness of Evolocumab in Reducing the Plaque Burden in Participants With Subclinical Atheroma

Not yet recruitingNCT07803679

AmgenCoronary Artery Disease, Hypercholesterolemia, Atheroma +1

Start: 2027-01-31End: 2029-04-30Target: 308Updated: 2026-09-10